Recent investigations have documented that constitutively activated phosphatidylinositol 3-kinase (PI3K)/Akt/mammali-
Introduction
Activation of the phosphatidylinositol 3-kinase(PI3K)/Akt signaling pathway plays a central role in cancer biology, conferring resistance both in vivo and in vitro to therapeutic treatments of various types of malignancies that include leukemias (1) (2) (3) . Upon activation, PI3K generates phosphatidylinositol 3,4,5 trisphosphate, which then activates a number of downstream targets, including Akt. A fundamental negative regulator of the PI3K/Akt pathway is the lipid phosphatase PTEN (phosphatase and tensin deleted on chromosome 10), which removes the 3-phosphate from phosphatidylinositol 3,4,5 trisphosphate, thus down-modulating PI3K/Akt signaling (2, 3) . A PI3K/Akt downstream target that plays an important role in tumorigenesis and drug resistance is mammalian target of rapamycin (mTOR; ref. 4) . mTOR phosphorylates p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). By doing so, mTOR increases synthesis of proteins that are important for cell cycle regulation. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder of lymphoblasts committed to the T-cell lineage (5) . Over the past 20 years, survival rates of T-ALL patients have improved, due to advances in therapeutic protocols (6) . Survival rates at 5 years for children and adolescents with T-ALL are 70% to 75%, whereas for adults, they are 35% to 40% (7) . Nevertheless, novel therapies aimed at improperly activated signaling pathways are needed to combat induction failure, relapse rate, and the development of drug-resistance in T-ALL patients (7) . Aberrant Notch-1 receptor signaling is a hallmark of T-ALL (8) . Fifty-percent of T-ALL patients display Notch-1 activating mutations (7) . As a consequence, the receptor is activated independently of the ligand (9) . Other Notch-1 mutations impair its degradation and result in a longer receptor half-life (9, 10) . When the intracellular portion of Notch-1 is released through cleavage mediated by g-secretase (GSI), it translocates to the nucleus where it affects gene expression (11) . Therefore, GSI inhibition could be exploited to abrogate aberrant Notch-1 signaling in T-ALL. However, the results of the first clinical trial testing the GSI inhibitor, MK-0752, in relapsed/ refractory T-ALL patients, showed no clinical responses and a high incidence of gastrointestinal toxicity (9) . Recently, it was shown that in T-ALL, activated Notch-1 leads to PI3K/Akt signaling upregulation by hairy and enhancer of split 1-mediated transcriptional repression of PTEN (12) . Other reports have highlighted that PTEN posttranslational inactivation through phosphorylation and oxidation could result in PI3K/Akt/mTOR activation in T-ALL (13) . These findings lend compelling weight for the application of PI3K/ Akt/mTOR inhibitors in T-ALL (14) . mTOR inhibitors are being evaluated for treatment of several types of tumors, including leukemias (15) . Rapamycin or its analogues, used alone or in combination with traditional chemotherapeutic drugs, have shown some promising effects in preclinical models of T-ALL (e.g., ref. 14). However, mTOR inhibitors are mainly cytostatic (16) and could hyperactivate Akt due to the existence of feedback loops between mTOR, PI3K, and Akt (17) . Recently, dual PI3K/mTOR inhibitors have been synthesized, including PI-103, a small molecule of the pyridofuropyrimidine class (18) . Because PI-103 targets class IA PI3K in addition to mTOR, it should not lead to Akt activation, which is seen when only mTOR is targeted by inhibitors (18) . Moreover, PI-103 should affect mTOR signaling also when it is activated independently from PI3K/Akt, as described in some T-ALL cases (19) . Here, we have analyzed the therapeutic potential of PI-103 on both T-ALL cell lines and patient samples. We have shown that this drug displays strong cytotoxic activity against T-ALL cells.
Materials and Methods
Materials. PI-103 was purchased from Alexis Biochemicals. Rapamycin, LY294002, and Wortmannin were from Sigma-Aldrich. P110a PI3K inhibitor [compound 15e or (3-[4-(4-Morpholinyl)thieno(3,2-d)pyrimidin-2-yl]-phenol)] was from Alexis, whereas p110h (TGX-221) and p110g (5-[2,2-Difluorobenzo(1,3)dioxol-5-ylmethylene]-thiazolidine-2,4-dione) PI3K inhibitors and Akt 1/2 inhibitor were from Calbiochem-Novabiochem. For Western blots, the following primary antibodies were from Cell Signaling Technology: h-actin, Akt, Ser 473 p-Akt (which recognizes both Akt1 and Akt2 when phosphorylated on Ser 473 and Ser 474, respectively), p70S6K, Thr 389 pp70S6K, 4E-BP1, Thr 37/46 p-4E-BP1, glycogen synthase kinase (GSK)-3h, Ser 21/9 p-GSK-3a/h, S6 ribosomal protein (S6RP), Ser 235/236 p-S6RP, p110g PI3K, caspase-3, and caspase-9. Antibodies to p110a, p110h, and p110y PI3K were from Upstate Biotechnology/Millipore Corporation. Antibodies to Akt1 (raised in goat) and Akt2 (raised in mouse) were from Santa Cruz Biotechnology.
Cell culture and patient samples. Cell viability analysis. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to assess the sensitivity of cells to PI-103 and other inhibitors, as previously reported (21) .
Annexin V-FITC/propidium iodide staining and cell cycle analysis. To assess the extent of apoptosis induction after treatments, flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained samples was performed, as reported elsewhere (21) . Samples were analyzed by an EPICS XL flow cytometer (Beckman Coulter). At least 15,000 events per sample were acquired. For cell cycle analysis, samples were stained with PI and analyzed by flow cytometry, as described elsewhere (21) . At least 10,000 events per sample were acquired.
Western blot analysis. Cells were collected by centrifugation, washed twice in PBS, and lysed as previously reported (21) . Samples were separated on SDS-polyacrylamide gels and electrotransferred to nitrocellulose membranes. Western blot analysis was performed as detailed elsewhere (20) . Each blot is representative of three separate experiments. Antibody to h-actin served as a loading control.
Immunoprecipitation. This was carried out according to others (22) . Cell extracts were incubated for 2 h at 4jC under constant agitation with 5 Ag of the antibody to either Akt1 or Akt2. Ten micrograms of 50% protein A/G agarose was then added and incubation proceeded for 1 h at 4jC under constant agitation.
Combined drug effect analysis. The combination effect and a potential synergy were evaluated from quantitative analysis of dose-effect relationships as described previously (22) . For each PI-103/vincristine drug combination experiment, a combination index number was calculated using the Biosoft CalcuSyn software. This method of analysis generally defines combination index values of 0.9 to 1.1 as additive, 0.3 to 0.9 as synergistic, and <0.3 as strongly synergistic, whereas values >1.1 are considered antagonistic.
Flow cytometric analysis of p-Akt, p-4E-BP1, and cleaved caspase-3 levels in T-ALL patient samples. Blasts from 7 pediatric patients with T-ALL were fixed in reagent 1 of the Intraprep kit and permeabilized with saponin-based reagent 2 (Beckman Coulter) as reported elsewhere (23, 24) . Cells were incubated with primary antibody to Ser473 p-Akt, Thr 37/46 p-4E-BP1, or cleaved caspase-3. All the antibodies were from Cell Signaling and were conjugated to AlexaFluor 488. A rabbit IgG conjugated to AlexaFluor 488 was used as an irrelevant antibody. Cells were analyzed on a FC500 flow cytometer (Beckman Coulter). At least 10,000 events per sample were acquired. The vehicle alone (DMSO) did not affect cell survival (data not shown). Remarkably, also the drug-resistant CEM-R cell line, a subclone overexpressing 170-kDa P-glycoprotein, showed sensitivity to PI-103 (IC 50 , 0.6 Amol/L at 24 hours and 0.25 Amol/L at 48 hours; Fig. 1A ). Next, a comparison was made between PI-103 and inhibitors of either mTOR (rapamycin) or PI3K (Wortmannin, LY294002). Rapamycin was less effective than PI-103 in negatively affecting cell growth of T-ALL cell lines, also when used at equimolar concentrations, (Fig. 1B) . Wortmannin was much less effective than PI-103 and the same was true of LY294002, which approached PI-103 cytotoxicity only when used at 25 to 50 Amol/L (Fig. 1B) .
Results

PI
It was next investigated whether decreased cell proliferation was related to apoptosis, using Annexin V-FITC/PI staining and flow cytometry. After 9 hours of treatment, f45% of CEM-R cells were apoptotic with 25% in early apoptosis (Annexin V-FITC positive only) and 20% mid/late apoptosis (Annexin V-FITC/PI positive), whereas f9% of CEM-S cells were positive for early apoptosis (Annexin V-FITC only) and another 33% were positive for both Annexin-V and PI, indicating mid/late apoptotic cells. The degree of apoptosis induced in MOLT-4 and Jurkat cells by PI-103 was similar to that detected in CEM-S cells (Supplementary Fig. S1A ). Both rapamycin and LY294002 were much less effective than PI-103 in inducing apoptosis ( Supplementary Fig. S1A ). Given the fundamental role played by PI3K/Akt/mTOR signaling in cell proliferation, the effects of PI-103 on cell cycle progression were also investigated. Flow cytometric analysis of PI-stained T-ALL cells treated with PI-103 for 16 hours documented an increase in G 0 -G 1 phase cells and a decrease in S and G 2 -M phase cells (Supplementary Fig. S1B ). As rapamycin is mainly cytostatic, we reasoned that MTT assay could not be the most appropriate technique to calculate its IC 50 . Therefore, we also performed flow cytometric analysis of cell cycle. However, as shown in Supplementary Fig. S2 , this technique also documented that the IC 50 was not reached even at 3 Amol/L rapamycin for CEM-R, CEM-S, and MOLT-4 cells, whereas for Jurkat cells the decrease in cell proliferation was around 50% at 3 Amol/L.
Overall, these findings showed that PI-103 potently reduced the growth of T-ALL cell lines and that this effect was due to both apoptosis and cell cycle arrest.
PI-103 induces caspase activation. A distinguishing feature of apoptotic cell death is the activation of a family of proteases called caspases, which are responsible for most of the biochemical and morphologic changes that characterize apoptosis (27) . Western blotting analysis of extracts from both CEM-R and MOLT-4 cells treated with PI-103 documented that cleavage of procaspase-9 and procaspase-3 was detectable at 8 hours of treatment. In contrast, rapamycin activated caspase-3 and caspase-9 only in MOLT-4 cells, and at a later time (16 h; Fig. 2) .
PI-103 affects PI3K/Akt/mTOR signaling in T-ALL cell lines. Western blot analysis with an antibody to Ser 473 p-Akt showed a marked decrease in this p-Akt form in response to 0.75 Amol/L PI-103 already after 8 hours of treatment (Fig. 3A) . Rapamycin (0.1 Amol/L) treatment transiently activated Ser 473 p-Akt at 8 hours, in agreement with others (28) . The p-Akt levels then decreased, but at 48 hours, they increased again. Total Akt levels were unaffected by either PI-103 or rapamycin. Akt inhibition by PI-103 had functional consequences because the well-established Akt downstream target, GSK3-h, showed a decreased phosphorylation level, whereas the expression of total GSK3-h was unaffected. p-GSK-3h behavior in response to rapamycin was similar to p-Akt in that it increased at 8 hours, then decreased and increased again at 48 hours. mTOR downstream substrates (p70S6K, 4E-BP1, and S6RP) were efficiently dephosphorylated by both PI-103 and rapamycin, with the exception of 4E-BP1 that was resistant to rapamycin (Fig. 3A) . A dose-dependent investigation carried on CEM-R cells showed that PI-103 induced Akt dephosphorylation already at 125 nmol/L, whereas 4E-BP1 dephosphorylation was detectable at 250 nmol/L (Fig. 3B) .
Characterization of PI3K/Akt signaling in T-ALL cells. No information is available regarding the class I PI3K catalytic subunits and Akt isoforms that are active in PTEN-negative T-ALL cell lines. This issue is relevant to cancer therapy, as Akt isoform-specific inhibitors are actively sought (29) . Moreover, inhibitors selective for class I PI3K catalytic subunits are being tested in clinical trials (30) . Immunoprecipitation experiments were performed on extracts from T-ALL cells using antibodies specific for either Akt1 or Akt2. The immunoprecipitates were blotted to nitrocellulose membranes that were then probed with the antibody used for the immunoprecipitation, or an antibody that recognizes both Akt1 or Akt2 when phosphorylated on Ser 473 and Ser 474, respectively. We found that T-ALL cell lines expressed both Akt1 and Akt2 that were phosphorylated (Fig. 4A) . As a control, the blots with the Akt1 immunoprecipitates were probed with the antibody to Akt2, and vice versa. The antibody to Akt2 picked up some bands in the Akt1 blots; however, the molecular weight of these bands did not correspond to Akt1 molecular weight (60 kDa). In contrast, the antibody to Akt1 did not pick up any bands in the Akt2 blots (Fig. 4A) .
T-ALL cell lines expressed p110a, p110h, p110g, and p110y PI3K, as shown by Western blot analysis (Fig. 4B) . We next examined the effects of p110 PI3K isoform selective inhibitors to establish which isoforms were involved in T-ALL cell survival (Fig. 4B) . We used compound 15e, which inhibits p110a PI3K with an IC 50 of 0.58 Amol/L (31), TGX-221, which displays an IC 50 of around 40 nmol/L for p110h PI3K (32), and 5-[2,2-Difluoro-benzo(1,3)-dioxol-5-ylmethylene]-thiazolidine-2,4-dione, which has an IC 50 of f250 nmol/L against p110g PI3K (33) . MTT assays were performed after 24 hours of treatment. A dose-dependent decrease in cell survival was obtained with the p110a PI3K selective inhibitor. In contrast, inhibitors of h and g p110 PI3K had either much lower (h) or no (g) effects (Fig. 4B) . No effects were observed with a p110 y PI3K-selective inhibitor (data not shown; ref. 32). Consistently, inhibition of Ser 473 p-Akt phosphorylation was maximally observed with the a inhibitor, and to a much lower extent with h inhibitor, whereas the g inhibitor actually increased Akt phosphorylation when used at 2 Amol/L (Fig. 4C) . The p110y PI3K inhibitor was ineffective in dephosphorylating Akt (data not shown). Immunoprecipitation experiments documented that the p110a PI3K inhibitor dephosphorylated both Akt1 and Akt2 in Jurkat cells. Also, PI-103 dephosphorylated both Akt isoforms (Fig. 4D) . However, when the p110a PI3K selective inhibitor was combined with rapamycin, the growth inhibition effect was not as strong as with PI-103. An allosteric Akt 1/2 inhibitor (34) was less effective than PI-103, when used at equimolar concentrations ( Supplementary Fig. S3A-B) . Also, this inhibitor was much less cytotoxic than PI-103 when used against CEM-R cells. Overall, these experiments showed that T-ALL cell lines display both p-Akt1 and p-Akt2 expression and that p110a PI3K is the most important isoform for their growth.
PI-103 synergizes with vincristine. It was investigated whether PI-103 could synergize with vincristine, a drug commonly used for treating T-ALL patients (35) . Previous reports have indicated that mTOR activation specifically confers resistance to chemotherapeutic drugs that target the microtubules, including vincristine (36) . T-ALL cell lines were incubated for 24 hours with vincristine alone, PI-103 alone, or the drugs together at a fixed ratio (PI-103/ vincristine, 25:1). MTT assays were then performed. The combined treatment was much more cytotoxic than either of the two drugs alone (Fig. 5A) . Analysis of the combination index documented the existence of a strong synergism (combination index, <0.3) at PI-103 concentrations that were well below the IC 50 (Fig. 5B) .
T-ALL blasts are sensitive to PI-103. To better assess the effectiveness of PI-103 as a potential therapeutic agent in T-ALL, we examined pediatric T-ALL patient samples isolated from bone marrow or peripheral blood, for the levels of Ser 473 p-Akt, and Thr 37/46 p-4E-BP1, as well as for their sensitivity to PI-103, using flow cytometry and MTT assays. The clinical features of T-ALL patients are presented in Supplementary Table S1. All patient samples (7 of 7) had higher levels of p-Akt and p-4E-BP1 than those detected in peripheral blood lymphocytes from healthy donors (data not shown; Fig. 6A ). Flow cytometric analysis documented a decrease in the levels of Ser 473 p-Akt in samples treated with PI-103 (Fig. 6B) . The same technique also showed increased levels Figure 4 . Expression of Akt1 and Akt2 and involvement of PI3K isoforms in T-ALL cell survival. A, immunoprecipitation analysis. Whole cell extracts were incubated with either Akt1 or Akt2 antibody followed by protein A/G-agarose immunoprecipitation. The immunoprecipitates (IP ) were probed with Ab (WB ) to Akt1, to p-Akt (which recognizes both Ser 473 p-Akt1 and Ser 474 p-Akt2), and Akt2. B, T-ALL cell lines expressed p110a PI3K, p110h PI3K, p110g PI3K, and p110y PI3K, as documented by Western blots. MTT assays of T-ALL cell lines, performed after 24 h of treatment, showed that only a p110a PI3K inhibitor (compound 15e) displayed a marked dose-dependent cytotoxicity. Columns, mean of at least three different experiments; bars, SD. C, Western blot analysis demonstrating that only compound 15e resulted in a marked dose-dependent down-regulation of p-Akt in both Jurkat and CEM-R cells. D, immunoprecipitation analysis performed on Jurkat cells documented that compound 15e and PI-103 dephosphorylated both Akt1 and Akt2. Experimental design is as in A. INPUT shows that the same amount of protein was present in lysates before immunoprecipitation.
of cleaved caspase-3 after treatment with PI-103, which were higher than in samples exposed to rapamycin (Fig. 6C) . To determine the susceptibility of T-ALL lymphoblasts to inhibition of PI3K/ Akt/mTOR signaling, the samples were treated with increasing concentrations of PI-103 for 96 hours, and cell survival was analyzed by MTT assays. A strong reduction of cell viability at 96 hours was detected. The IC 50 for patient samples ranged between 0.18 and 0.63 Amol/L PI-103. Overall, these findings showed that PI-103 has a potent cytotoxic activity and activated caspase-3 also in primary cells from T-ALL patients with up-regulated PI3K/Akt/ mTOR signaling.
Discussion
The PI3K/Akt/mTOR pathway is a recently identified potential target for therapeutic intervention in T-ALL. Here, we have shown that PI-103 has a strong cytotoxic activity against T-ALL cell lines and lymphoblasts derived from T-ALL patients. Thus far, the antiproliferative effects of PI-103 have been mainly documented in glioblastomas (18) and in acute myeloid leukemia (AML) cells (37, 38) . PI-103 cytotoxicity in T-ALL cell lines was independent of the p53 gene status. It should be emphasized that p53 mutations are associated with a much worse prognosis in T-ALL patients (39) . Our findings are different to those reported for AML cell lines, where the modest cytotoxic effect of PI-103 could be enhanced by the murine double minute-2 inhibitor, Nutlin-3, in a wild-type p53-dependent fashion (38) . In this respect, our results are in agreement with those reported for glioblastoma cell lines, where PI-103 was cytototoxic independently of the p53 gene status (18) .
Moreover, PI-103 was effective also against a CEM cell subclone, CEM-R, which overexpresses high levels of 170-kDa P-glycoprotein, one of the main determinants of drug resistance. This observation is relevant, as 170 kDa P-glycoprotein is detected in f24% of T-ALL patients and negatively correlates with the achievement of a complete remission (40, 41) . In T-ALL cell lines, PI-103 induced both G 0 -G 1 phase cell cycle arrest and apoptosis, which was characterized by activation of caspase-9 and caspase-3. In contrast, in AML cell lines, PI-103 was mainly cytostatic and did not induce apoptosis or only had a modest apoptogenic activity (37, 38) . PI-103 was capable of dephosphorylating Akt and its downstream target, GSK-3h, as well as mTOR downstream targets. PI-103 strongly synergized with vincristine, a drug used in treating T-ALL patients. Remarkably, PI-103 displayed cytotoxic activity against lymphoblasts from patients with pediatric T-ALL characterized by enhanced levels of p-Akt and p-4E-BP1. Also, in patient samples, PI-103 dephosphorylated Akt and activated caspase-3.
In our hands, PI-103 was more effective than rapamycin alone in negatively affecting growth of T-ALL cells, even when used on an equimolar basis. PI-103 was also more effective than Wortmannin, an irreversible PI3K inhibitor. LY294002, a reversible PI3K inhibitor, displayed a potency that approached that of PI-103 only when used at extremely high concentrations.
Because rapamycin and its analogues only target mTORC1 and not mTORC2 (which is responsible for Ser 473 p-Akt phosphorylation; ref. 17) , it has been shown that the use of these inhibitors could indeed result in Akt hyperactivation (28) . Consistently, we have observed that rapamycin treatment of T-ALL cell lines resulted in Akt hyperactivation at 8 and 48 hours. Also the Akt substrate GSK-3h displayed hyperphosphorylation at the same times, implying an activation of Akt by rapamycin. In contrast, PI-103, which has been documented to inhibit both mTORC1 Figure 5 . A PI-103 and vincristine combination is synergistic in MOLT-4, JURKAT, and CEM-S cell lines. A, cells were cultured in presence of vincristine (VCR ) and PI-103 alone, or in combination, at a fixed ratio (1:25) . The combined treatment was highly effective in inducing cytotoxicity, as shown by MTT assays at 24 h. Points, mean of at least three different experiments; bars, SD. B, the combination index value for each data point was calculated with the appropriate software for dose effect analysis (CalcuSyn). and mTORC2 activity (18) , did not hyperactivate Akt in T-ALL cells, even at later incubation times, and this might be related to mTORC2 inhibition. A previous report highlighted that in Jurkat cells, prolonged treatment with rapamycin inhibited mTORC2 at 24 hours (42) . However, that study did not examine later times. At present, we do not know if the hyperphosphorylation of Akt we observed after 48 hours of treatment with rapamycin was due to a low stability of the drug in vitro or to other reason(s). Interestingly, PI-103, but not rapamycin, dephosphorylated 4E-BP1. This might be due to the fact that, in T-ALL cells, 4E-BP1 is downstream of PIM kinases and not of mTORC1. This would not be unprecedented, as it has been recently shown to occur in AML cells (43) . Therefore, we could hypothesize that PI-103, by blocking PI3K/Akt, would result also in PIM kinase downregulation, as PIM kinases have been reported to be downstream of PI3K/Akt (44) . Lack of 4E-BP1 dephosphorylation by rapamycin could also explain why the drug is less efficacious than PI-103 against T-ALL cell lines.
We also have shown for the first time that T-ALL cell lines express Akt1 and Akt2. Both of these isoforms were constitutively phosphorylated, and PI-103 down-regulated their phosphorylation levels. Another new finding emerging from our study is that in T-ALL cell lines, p110a PI3K, seems to be the most important isoform for cell growth and Akt1/Akt2 phosphorylation. PI-103 was originally described as a compound specifically targeting p110a PI3K (18) , although subsequent investigations have highlighted that it also inhibited other class IA PI3Ks (37) . However, a combination of rapamycin plus the p110a PI3K inhibitor, 15e, was less effective than PI-103. Also, an Akt1/Akt2 allosteric inhibitor was less effective than PI-103.
In conclusion, we have provided evidence that PI-103, either alone or in combination with vincristine, is a highly effective drug against T-ALL cells, also derived from patients. It displayed cytotoxic activity against cells with activating Notch-1 mutations, such as Jurkat and MOLT-4, which are resistant to GSI (26) .
PI-103 has proven efficacy also in vivo against models of human tumors xenografted in mice, where it displayed low toxicity and was well-tolerated (18, 28) . Interestingly, in a mouse model of Bcr-Abl + B-ALL, PI-103 was less effective than rapamycin (45) . This could reflect important biological differences between T-ALL and Bcr-Abl + B-ALL, which, however, remain to be elucidated. In any case, hypersensitivity of Bcr-Abl + B-ALL cell lines to rapamycin has been recently reported also by another group (46) . PI-103 did not induce apoptosis in normal human CD34 + cells and had moderate effects on their clonogenicity and proliferation (37) . This could indicate that dual targeting of PI3K/mTOR signaling would not detrimentally affect normal hematopoiesis in humans.
PI-103 did not enter clinical trials mainly because of its rapid in vivo metabolism (47) . Nevertheless, we feel that our findings strongly support the hypothesis that longitudinal inhibition at two nodes of the PI3K/Akt/mTOR pathway in T-ALL cells could ensue in more effective results than the use of a single inhibitor targeting either PI3K or mTOR.
Recently, a new orally available dual PI3K/mTOR inhibitor, NVP-BEZ235, has entered phase I clinical trials (48) . It will be interesting to test if NVP-BEZ235 is as effective as PI-103 against T-ALL cells. These investigations could pave the way for using dual PI3K/ mTOR inhibitors to improve the therapeutic outcome of T-ALL patients displaying activation of PI3K/Akt/mTOR signaling.
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